Last reviewed · How we verify
Placebo Gefitinib Tablets
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Used for Non-small cell lung cancer, Locally advanced or metastatic non-small cell lung cancer.
At a glance
| Generic name | Placebo Gefitinib Tablets |
|---|---|
| Sponsor | Hangzhou ACEA Pharmaceutical Research Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by selectively inhibiting the tyrosine kinase activity of the EGFR, thereby blocking the signal transduction pathways that lead to cell proliferation and survival. This results in the inhibition of tumor growth and metastasis.
Approved indications
- Non-small cell lung cancer
- Locally advanced or metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Rash
- Nausea
- Vomiting
- Fatigue
- Anorexia
- Dyspnea
- Cough
- Pneumonia
- Acute respiratory distress syndrome
Key clinical trials
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) (PHASE3)
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients (PHASE3)
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (PHASE1, PHASE2)
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- Anticancer Activity of Nicotinamide on Lung Cancer (PHASE2, PHASE3)
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma (PHASE3)
- Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation (PHASE3)
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Gefitinib Tablets CI brief — competitive landscape report
- Placebo Gefitinib Tablets updates RSS · CI watch RSS
- Hangzhou ACEA Pharmaceutical Research Co., Ltd. portfolio CI